Before entering the phase I of clinical trials all innovative drugs are tested on animals in order to confirm their efficacy and safety.
For the proof-of-concept testing adequate animal models, that would reflect the clinical manifestation of the targeted disease, are needed. In oncology, in vivo studies are conducted on xenografts – immunodeficient animals transplanted with cancer cells of particular type. Drug candidates for metabolic disorders require diabetic or obese animals for in vivo testing, and in the case of Alzheimer’s disease and other disorders associated with cognitive decline - a wide range of behavioral tests are applied.
Concurrently, pharmacokinetic studies are performed to asses stability and metabolism of each novel drug. It is also essential to run toxicology tests that allow to confirm safety of investigated drug.
We carry out all in vivo preclinical research in collaboration with the leading scientific institutions including: BioTest, Experimental Medicine Centre in Bialystok, Tri-City Central Animal Laboratory in Gdansk, Nencki Institute of Experimental Biology PAS in Warsaw, Institute of Immunology and Experimental Therapy in Wroclaw and others.